This work is focused on the research on how to leverage 3D printing technology in the field of cell transplantation. More specifically, the study of an artificial organ for hormone replacement therapies thanks to the close collaboration between the Methodist Hospital Research Institute, Houston, Texas and Politecnico di Torino, Turin, Italy. Cell transplantation offers an attractive therapeutic approach for many endocrine deficiencies. Transplanted endocrine cells or engineered cells encapsulated in the here presented 3D printed device, can act as biological sensors detecting changes in hormonal levels and secrete molecules in response to maintain homeostasis. The major advantage of this technology is that patients affected by endocrine disorder could potentially avoid the need of frequent hormone injections, such as insulin or testosterone, resulting in an improved quality of life and lower chronic side effects associated to external hormone supplementations. This implant was extensively tested both in vitro and in vivo condition, providing remarkable results that lead to several publications. The cell encapsulation system was fabricated via 3D printing technology adopting an FDA approved polymeric material. The structure, composed by an array of micro and macro channels, was specifically designed in order to allow vasculature formation within the device and for housing cells while avoiding cell clustering. Over the course of the Ph.D., the technology was designed, fabricated and tested for the encapsulation of several cell lines and for small and large animal models. According to the in vivo results, we demonstrated that our 3D printed device exemplifies a clinically translatable strategy for preserving viability and function of transplanted cells. Currently, is ongoing an experiment in Non-Human Primates (data not shown), last pre- clinical study before the possibility to move to the clinical development in humans. The pre-vascularization approach to achieve an ideal intra-device milieu prior to transplantation, transcutaneous cell loading and refilling capabilities, as well as the potential for rapid device retrievability, addresses current challenges in transplantation. This technology may offer exciting potential for clinical adoption in relevant medical areas of diabetes, hypogonadism, hypothyroidism, cancer, and neurological diseases among others.

Implantable medical devices for drug and cell release / Farina, Marco. - (2018 May 31).

Implantable medical devices for drug and cell release

FARINA, MARCO
2018

Abstract

This work is focused on the research on how to leverage 3D printing technology in the field of cell transplantation. More specifically, the study of an artificial organ for hormone replacement therapies thanks to the close collaboration between the Methodist Hospital Research Institute, Houston, Texas and Politecnico di Torino, Turin, Italy. Cell transplantation offers an attractive therapeutic approach for many endocrine deficiencies. Transplanted endocrine cells or engineered cells encapsulated in the here presented 3D printed device, can act as biological sensors detecting changes in hormonal levels and secrete molecules in response to maintain homeostasis. The major advantage of this technology is that patients affected by endocrine disorder could potentially avoid the need of frequent hormone injections, such as insulin or testosterone, resulting in an improved quality of life and lower chronic side effects associated to external hormone supplementations. This implant was extensively tested both in vitro and in vivo condition, providing remarkable results that lead to several publications. The cell encapsulation system was fabricated via 3D printing technology adopting an FDA approved polymeric material. The structure, composed by an array of micro and macro channels, was specifically designed in order to allow vasculature formation within the device and for housing cells while avoiding cell clustering. Over the course of the Ph.D., the technology was designed, fabricated and tested for the encapsulation of several cell lines and for small and large animal models. According to the in vivo results, we demonstrated that our 3D printed device exemplifies a clinically translatable strategy for preserving viability and function of transplanted cells. Currently, is ongoing an experiment in Non-Human Primates (data not shown), last pre- clinical study before the possibility to move to the clinical development in humans. The pre-vascularization approach to achieve an ideal intra-device milieu prior to transplantation, transcutaneous cell loading and refilling capabilities, as well as the potential for rapid device retrievability, addresses current challenges in transplantation. This technology may offer exciting potential for clinical adoption in relevant medical areas of diabetes, hypogonadism, hypothyroidism, cancer, and neurological diseases among others.
31-mag-2018
File in questo prodotto:
File Dimensione Formato  
Thesis Marco Farina.pdf

Open Access dal 01/06/2019

Descrizione: Tesi dottorato
Tipologia: Tesi di dottorato
Licenza: PUBBLICO - Tutti i diritti riservati
Dimensione 3.79 MB
Formato Adobe PDF
3.79 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11583/2709325
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo